Alterity Therapeutics Presents to Finance News Network

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – June 4, 2019. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is participating in the Finance News Network investor event today in Sydney.

The event attracts a large number of retail, high net worth and sophisticated investors. The presentation follows the company’s strong presence at the American Neurology Association annual meeting last month and the release of clinical data from its Phase 1 clinical trial for its lead investigational drug PBT434.

This study has shown that PBT434 was well tolerated with adverse event rates comparable to placebo and dose dependent systemic exposure following oral administration. Importantly, the results indicated that
PBT434 not only crosses the blood brain barrier in humans, confirming previous observations in animal studies, but that clinically tested doses achieve concentrations in brain that exceed those associated with
efficacy in animal models of disease. No serious adverse events were reported and no subject discontinued dosing with PBT434 due to adverse events.

Mr Geoffrey Kempler, CEO and Chairman will be presenting at the event which is taking place at the Radisson Blu Plaza Hotel in Sydney between 12:30pm and 2:30pm. The event is free and attendees can register here. 

Mr Kempler will also be meeting with investors in Sydney. Alterity Therapeutics’ presentation is available below for download.